Himalaya Nutravedics India Limited

Total Issue Size

₹26.5 Cr

24,99,600 shares

Fresh Issue

₹26.5 Cr

24,99,600 shares

Offer for Sale

₹0 Cr

Face Value

₹10 per share

Issue Type

Book-built IPO

Listing At

BSE SME

Shares Pre-Issue

63,06,720

Shares Post-Issue

88,06,320

1. Offer opens

   22 Sept 2026

2. Offer closes

   24 Sept 2026

3. Allotment

   25 Sept 2026

4. Listing

   29 Sept 2026

• Anchor28.4%7,10,400 shares
• QIB19.0%4,74,000 shares
• HNI14.3%3,56,400 shares
• Retail33.3%8,32,800 shares
• MarketMaker5.0%1,26,000 shares

Subscription figures will appear here once bidding opens on 22 Sept 2026.

Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. The Company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements. Its products are available in multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. The products cater to therapeutic and wellness areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women’s wellness and general wellness. Himalaya Nutravedics operates through a hybrid business model comprising its own branded products and third-party contract manufacturing. Under its own-brand business, the Company develops, manufactures and markets Ayurvedic and nutraceutical products, while its third-party manufacturing business provides formulation, manufacturing, packaging and dispatch services based on client specifications. As of March 31, 2026, its own-brand business contributed approximately ₹2,202.54 lakh, representing about 51.14% of total revenue. The Company operates an integrated manufacturing facility in Hyderabad, Telangana, where formulation, production, quality control, packaging and finished-goods release are carried out internally. The facility is compliant with WHO-GMP standards and holds registrations and licences from AYUSH and FSSAI, along with certifications including ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER. As of July 31, 2026, the Company had 86 full-time employees across marketing, factory, finance, quality, compliance and administration functions. Competitive Strengths Geographic expansion across India. Long-standing supplier and customer relationships. Integrated multi-dosage manufacturing capabilities. Doctor acceptance supported by product performance. Broad therapeutic coverage across Ayurvedic and nutraceutical segments

• Funding Working Capital Requirements (₹13.75 Cr)
• Business Development and Digital Marketing Activities (₹7.50 Cr)
• General Corporate Purposes

• <p>Rohit Asawa
• Divya Asawa
• Chanda Asawa
• Rama Raju Penmatsa</p>

Book running lead managers

• Nirbhay Capital Services Pvt.Ltd.

Registered office

Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad, Telangana, 500051

Market maker

Allwin Securities Ltd.

• DRHPDraft Red Herring Prospectus
• RHPRed Herring Prospectus